C. O'brien

发表

Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes

Thomas D. Wu, Brock A. Peters, Guy Cavet, 2009, Molecular Cancer Research.

TRPS1 Targeting by miR-221/222 Promotes the Epithelial-to-Mesenchymal Transition in Breast Cancer

Ru-Fang Yeh, Richard Bourgon, Zachary Boyd, 2011, Science Signaling.

Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models

E. Sokol, T. Wilson, L. Friedman, 2019, Molecular Cancer Therapeutics.

Abstract S2-02: The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer – Part I results

M. Ellis, E. Winer, E. Perez, 2015 .

In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models

Wei Zhou, Guy Cavet, Zachary Boyd, 2009, Clinical Cancer Research.

Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors.

Petra Ross-Macdonald, Yvonne Franke, Carol O'Brien, 2005, Cancer cell.

Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models

M. Belvin, D. Guhathakurta, L. Amler, 2010, Clinical Cancer Research.

The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase

R. Neve, T. Wilson, K. Hoeflich, 2016, Genes & cancer.

GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

M. Belvin, J. Spoerke, D. Sutherlin, 2011, Molecular Cancer Therapeutics.

GDC-0980IsaNovelClassIPI3K/mTORKinaseInhibitorwith RobustActivityinCancerModelsDrivenbythePI3KPathway

M. Belvin, J. Spoerke, D. Sutherlin, 2011 .

PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

J. Mackey, N. Robert, W. Eiermann, 2015, Clinical Cancer Research.

Loss Is Associated with Worse Outcome in HER 2-Ampli fi ed Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

J. Mackey, P. Nuciforo, D. Slamon, 2015 .

Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer

G. Hampton, Yulei N. Wang, T. Wilson, 2013, Oncogenesis.

Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.

M. Belvin, S. Seshagiri, Z. Modrušan, 2009, Cancer research.

The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population

G. Hampton, J. Fridlyand, T. Wilson, 2016, npj Breast Cancer.

miR-221/222 Targeting of Trichorhinophalangeal 1 (TRPS1) Promotes Epithelial-to-Mesenchymal Transition in Breast Cancer

R. Bourgon, R. Yeh, A. Adai, 2011, Science Signaling.

Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models

G. Hampton, J. Fridlyand, J. Spoerke, 2012, Clinical Cancer Research.

Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer.

Guy Cavet, Carol O'Brien, Zora Modrusan, 2008, Cancer research.

Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β.

G. Hampton, K. Walter, J. Spoerke, 2016, Cancer research.

Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays

Yibing Yan, Carol O'Brien, J. Spoerke, 2008, Molecular Cancer Therapeutics.

Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer

G. Cavet, Xiaolan Hu, J. Zha, 2009, Molecular Cancer Therapeutics.

ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors

Wei Zhou, William F. Forrest, Sherry Heldens, 2012, Molecular Cancer Therapeutics.

Targeted Biomarker Profiling of Matched Primary and Metastatic Estrogen Receptor Positive Breast Cancers

G. Hampton, T. Wilson, J. Spoerke, 2014, PloS one.